NCT02117050View on ClinicalTrials.gov

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

PHASE4TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Multiple Sclerosis
Interventions
DRUG

Rebif®

Rebif® will be administered subcutaneously three times a week at a dose of 8.8 to 44 microgram (mcg) in initial titration schedule (5 weeks), followed by Rebif® 44 mcg subcutaneously three times a week by using Rebif® Rebidose® auto-injector device till Week 24.

Trial Locations (1)

Unknown

Call EMD Serono Medical Information for information on recruiting sites, Boston

Sponsors

Lead Sponsor

EMD Serono
All Listed Sponsors
lead

EMD Serono

INDUSTRY

NCT02117050 - RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate | Biotech Hunter | Biotech Hunter